Since Wednesday, a new exchange-traded fund issued by VanEck has been tradable on Xetra and via Börse Frankfurt.
The VanEck Genomics and Healthcare Innovators UCITS ETF offers investors access to sustainable companies in the field of genomic and digital healthcare.
Genomics companies are developing new ways to treat health problems such as genetic disorders, cancer, and age-related diseases. These include gene therapies, including laboratory equipment and services for testing and coding, which primarily treat genetic diseases.
Digital healthcare focuses on easy access to doctors, physiotherapists, nurses, and pharmacies. Business areas such as software providers for telemedicine and administration, online pharmacies, and ambulatory internet of things for remote monitoring of health indicators are considered.
|Name||Asset class||ISIN||On-going charges||Distribution policy||Reference index|
|VanEck Ge-nomics and Healthcare In-novators UCITS ETF||Equity-ETF||IE000B9PQW54||0.35 per cent||accumulating||MVIS Global Future Healthcare ESG Index|
The product offering in Deutsche Börse’s XTF segment currently comprises a total of 1,932 ETFs. With this selection and an average monthly trading volume of around €19 billion, Xetra is the leading trading venue for ETFs in Europe.